Trials / Completed
CompletedNCT05873439
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
A Feasibility Study of Genomically Guided Radiation Dose Personalization in the Management of Locally Advanced Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
Conditions
- Nonsmall Cell Lung Cancer
- Nonsmall Cell Lung Cancer, Stage II
- Nonsmall Cell Lung Cancer Stage III
- Unresectable Non-Small Cell Lung Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Genomically Guided Radiation Therapy (RT) | Based on the Radiosensitivity Index (RSI) from testing participants tumor sample, participants will receive either standard dose radiation therapy, which is a strength 60Gy or up to 81Gy strength. Radiation treatment is administered 5 days per week for approximately 6 weeks. |
Timeline
- Start date
- 2023-05-25
- Primary completion
- 2023-11-29
- Completion
- 2024-08-21
- First posted
- 2023-05-24
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05873439. Inclusion in this directory is not an endorsement.